Recruiting

IV & SC Immunotherapy

Sponsor:

University of Southern California

Code:

NCT07339254

Conditions

Lung Non-Small Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Non-Interventional Study

Study Details

Brief summary:

This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.

Conditions

Lung Non-Small Cell Carcinoma

Study ID

NCT07339254

Start date

Mar 12, 2026

Status verified date

Mar, 2026

Completion date

Mar 12, 2028

Anticipated

Primary completion date

Mar 12, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • \* Age ≥ 18 years.
  • \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
  • \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
  • \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.

Exclusion Criteria:

  • \* Patients is unable to consent for themselves
  • \* Patient has not yet completed the 1st cycle of ICI-based therapy

Study Design

Enrollment

40 participants

Anticipated

Interventions and Outcome Measures

Arms

Observational

Patients complete surveys on study.

Interventions

Non-Interventional Study

Non-interventional study

Primary outcome measure

  • Strength of patient perception of Intravenous (IV) Immune Checkpoint Inhibitor (ICI) therapy [ Time Frame: At Baseline through study completion, up to 1 year. ]
  • Patient interest in home SC ICI administration vs. IV ICI administration at the infusion center [ Time Frame: At Baseline through study completion, up to 1 year. ]

Central Contacts and Locations

Locations

Los Angeles General Medical Center

Recruiting

Los Angeles, California, United States, 90033

Contacts

Sandy Tran

323-865-3000sandy.tran@med.usc.edu

Principal Investigator:

Robert Hsu

USC / Norris Comprehensive Cancer Center

Recruiting

Los Angeles, California, United States, 90033

Contacts

Sandy Tran

323-865-3000sandy.tran@med.usc.edu

Principal Investigator:

Robert Hsu

More Information

Sponsor

University of Southern California

Last update posted

Mar 16, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Southern California on 2026-03-16.